REG - Aptamer Group PLC - New Development Contract

AptamerAnnouncement

19/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241219:nRSS6662Qa&default-theme=true

RNS Number : 6662Q  Aptamer Group PLC  19 December 2024

 

19 December 2024

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

New Development Contract

 

Agreement worth up to £155,000 and potential for significant IP transfer fee
payment upon success

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, today announces the
signing of a new development contract with a rare disease biopharmaceutical
company. The agreement, worth up to £155,000, focuses on developing two
Optimer binders as critical reagents for therapeutic monitoring. Upon
successful development, Aptamer could receive a significant undisclosed IP
transfer fee for the use of the Optimers in clinical trial monitoring.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "This
agreement further demonstrates our strategic model of leveraging
fee-for-service revenue for the development of Optimer binders and potential
licensing revenues.

 

With a healthy pipeline and increasing traction among both new and repeat
customers, we are demonstrating our commercial strategy. These advancements
align with our broader vision of driving shareholder value by pairing
fee-for-service income with scalable licensing opportunities. We remain
focused on delivering on our growth objectives and look forward to sharing
updates on our continued progress."

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Adam Dawes 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group plc

 

Aptamer Group is a leading global developer of aptamer-based ligands that help
scientists remove the limits to discovery and innovation. Leveraging a
proprietary discovery and development platform, Aptamer delivers custom
affinity ligands, supported with a complete suite of characterisation and
validatory assays that enhance the translation of its binders and optimise
scientific outcomes for customers.

 

Aptamer's cutting-edge technology spans healthcare, research, personal care,
and industrial processes, delivering new affinity solutions for novel targets,
advanced diagnostics, and precision therapies. By working with industry
leaders in pharmaceutical, biotechnology, personal health, academic, and
clinical research sectors, Aptamer is accelerating science through the custom
development of tools and therapies.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTQKFBNDBDBDBD